{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:55:46Z","timestamp":1760954146539},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T00:00:00Z","timestamp":1327536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12015-011-9344-5","type":"journal-article","created":{"date-parts":[[2012,1,25]],"date-time":"2012-01-25T07:17:40Z","timestamp":1327475860000},"page":"994-1010","source":"Crossref","is-referenced-by-count":39,"title":["Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches"],"prefix":"10.1007","volume":"8","author":[{"given":"Crist\u00f3bal","family":"Aguilar-Gallardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Cecilia","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Mart\u00ednez-Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,26]]},"reference":[{"key":"9344_CR1","unstructured":"National Cancer Institute: Surveillance epidemiology and End Results. http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html.Retrieved December 18, 2010."},{"key":"9344_CR2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2008","unstructured":"Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2008). Estimates of cancer incidence and mortality in Europe in. European Journal of Cancer, 46, 765\u2013781.","journal-title":"European Journal of Cancer"},{"key":"9344_CR3","unstructured":"European commission: Public Health. Available at: http:\/\/ec.europa.eu\/health\/ph_information\/dissemination\/diseases\/cancer.htm . Retrieved December 15, 2010."},{"key":"9344_CR4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2008.12.002","volume":"36","author":"MM Leitao Jr","year":"2009","unstructured":"Leitao, M. M., Jr., & Chi, D. S. (2009). Surgical management of recurrent ovarian cancer. Seminars in Oncology, 36, 106\u2013111.","journal-title":"Seminars in Oncology"},{"key":"9344_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminoncol.2008.12.001","volume":"36","author":"C Krasner","year":"2009","unstructured":"Krasner, C., & Duska, L. (2009). Management of women with newly diagnosed ovarian cancer. Seminars in Oncology, 36, 91\u2013105.","journal-title":"Seminars in Oncology"},{"key":"9344_CR6","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983\u20133988.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9344_CR7","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65, 10946\u201310951.","journal-title":"Cancer Research"},{"key":"9344_CR8","doi-asserted-by":"crossref","first-page":"10158","DOI":"10.1073\/pnas.0703478104","volume":"104","author":"P Dalerba","year":"2007","unstructured":"Dalerba, P., Dylla, S. J., Park, I. K., et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 10158\u201310163.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9344_CR9","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","volume":"67","author":"C Li","year":"2007","unstructured":"Li, C., Heidt, D. G., Dalerba, P., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67, 1030\u20131037.","journal-title":"Cancer Research"},{"key":"9344_CR10","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","volume":"64","author":"R Galli","year":"2004","unstructured":"Galli, R., Binda, E., Orfanelli, U., et al. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Research, 64, 7011\u20137021.","journal-title":"Cancer Research"},{"key":"9344_CR11","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh, S. K., Clarke, I. D., Terasaki, M., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63, 5821\u20135828.","journal-title":"Cancer Research"},{"key":"9344_CR12","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang, S., Balch, C., Chan, M. W., et al. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Research, 68, 4311\u20134320.","journal-title":"Cancer Research"},{"key":"9344_CR13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2008.374","volume":"28","author":"T Baba","year":"2009","unstructured":"Baba, T., Convery, P. A., Matsumura, N., et al. (2009). Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene, 28, 209\u2013218.","journal-title":"Oncogene"},{"key":"9344_CR14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/stem.236","volume":"27","author":"MD Curley","year":"2009","unstructured":"Curley, M. D., Therrien, V. A., Cummings, C. L., et al. (2009). CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells, 27, 2875\u20132883.","journal-title":"Stem Cells"},{"key":"9344_CR15","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","volume":"65","author":"SA Bapat","year":"2005","unstructured":"Bapat, S. A., Mali, A. M., Koppikar, C. B., & Kurrey, N. K. (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Research, 65, 3025\u20133029.","journal-title":"Cancer Research"},{"key":"9344_CR16","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","volume":"66","author":"MF Clarke","year":"2006","unstructured":"Clarke, M. F., Dick, J. E., Dirks, P. B., et al. (2006). Cancer stem cells\u2013perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Research, 66, 9339\u20139344.","journal-title":"Cancer Research"},{"key":"9344_CR17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier, C., Hur, M. H., Charafe-Jauffret, E., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555\u2013567.","journal-title":"Cell Stem Cell"},{"key":"9344_CR18","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1038\/sj.onc.1207947","volume":"23","author":"M Al-Hajj","year":"2004","unstructured":"Al-Hajj, M., & Clarke, M. F. (2004). Self-renewal and solid tumor stem cells. Oncogene, 23, 7274\u20137282.","journal-title":"Oncogene"},{"key":"9344_CR19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12015-009-9096-7","volume":"5","author":"A Ruiz-Vela","year":"2009","unstructured":"Ruiz-Vela, A., Aguilar-Gallardo, C., & Simon, C. (2009). Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Reviews, 5, 319\u2013327.","journal-title":"Stem Cell Reviews"},{"key":"9344_CR20","doi-asserted-by":"crossref","unstructured":"Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u201353.","DOI":"10.1056\/NEJMoa0908806"},{"key":"9344_CR21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1053\/beog.2002.0304","volume":"16","author":"PE Schwartz","year":"2002","unstructured":"Schwartz, P. E. (2002). Neoadjuvant chemotherapy for the management of ovarian cancer. Best Practice & Research. Clinical Obstetrics & Gynaecology, 16, 585\u2013596.","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"key":"9344_CR22","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/jnci\/djj495","volume":"98","author":"TM Phillips","year":"2006","unstructured":"Phillips, T. M., McBride, W. H., & Pajonk, F. (2006). The response of CD24(-\/low)\/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute, 98, 1777\u20131785.","journal-title":"Journal of the National Cancer Institute"},{"key":"9344_CR23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao, S., Wu, Q., McLendon, R. E., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756\u2013760.","journal-title":"Nature"},{"key":"9344_CR24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4161\/cbt.6.11.5167","volume":"6","author":"MV Blagosklonny","year":"2007","unstructured":"Blagosklonny, M. V. (2007). Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biology & Therapy, 6, 1684\u20131690.","journal-title":"Cancer Biology & Therapy"},{"key":"9344_CR25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/j.1349-7006.2008.00914.x","volume":"99","author":"H Ishii","year":"2008","unstructured":"Ishii, H., Iwatsuki, M., Ieta, K., et al. (2008). Cancer stem cells and chemoradiation resistance. Cancer Science, 99, 1871\u20131877.","journal-title":"Cancer Science"},{"key":"9344_CR26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646\u2013674.","journal-title":"Cell"},{"key":"9344_CR27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta, P. B., Onder, T. T., Jiang, G., et al. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138, 645\u2013659.","journal-title":"Cell"},{"key":"9344_CR28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","volume":"29","author":"DG DeNardo","year":"2010","unstructured":"DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010). Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Reviews, 29, 309\u2013316.","journal-title":"Cancer Metastasis Reviews"},{"key":"9344_CR29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140, 883\u2013899.","journal-title":"Cell"},{"key":"9344_CR30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian, B. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141, 39\u201351.","journal-title":"Cell"},{"key":"9344_CR31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","volume":"449","author":"AE Karnoub","year":"2007","unstructured":"Karnoub, A. E., Dash, A. B., Vo, A. P., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449, 557\u2013563.","journal-title":"Nature"},{"key":"9344_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1748-717X-4-29","volume":"4","author":"PC Lara","year":"2009","unstructured":"Lara, P. C., Lloret, M., Clavo, B., et al. (2009). Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiation Oncology, 4, 29.","journal-title":"Radiation Oncology"},{"key":"9344_CR33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10585-010-9315-2","volume":"27","author":"S Elloul","year":"2010","unstructured":"Elloul, S., Vaksman, O., Stavnes, H. T., Trope, C. G., Davidson, B., & Reich, R. (2010). Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clinical & Experimental Metastasis, 27, 161\u2013172.","journal-title":"Clinical & Experimental Metastasis"},{"key":"9344_CR34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/stem.415","volume":"28","author":"F Pistollato","year":"2010","unstructured":"Pistollato, F., Abbadi, S., Rampazzo, E., et al. (2010). Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem cells Dayton, Ohio, 28, 851\u2013862.","journal-title":"Stem cells Dayton, Ohio"},{"key":"9344_CR35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/path.1778","volume":"206","author":"AE Greijer","year":"2005","unstructured":"Greijer, A. E., van der Groep, P., Kemming, D., et al. (2005). Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). The Journal of Pathology, 206, 291\u2013304.","journal-title":"The Journal of Pathology"},{"key":"9344_CR36","doi-asserted-by":"crossref","unstructured":"Levine, A.J., Puzio-Kuter, A.M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 3;330(6009):1340\u20134.","DOI":"10.1126\/science.1193494"},{"key":"9344_CR37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GIM.0b013e31818b0d9b","volume":"10","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis, R. J. (2008). Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genetics in Medicine, 10, 767\u2013777.","journal-title":"Genetics in Medicine"},{"key":"9344_CR38","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1517\/17425250902973711","volume":"5","author":"MA Hildebrandt","year":"2009","unstructured":"Hildebrandt, M. A., Gu, J., & Wu, X. (2009). Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opinion on Drug Metabolism & Toxicology, 5, 745\u2013755.","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"9344_CR39","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1158\/1078-0432.CCR-06-0564","volume":"12","author":"P Surowiak","year":"2006","unstructured":"Surowiak, P., Materna, V., Kaplenko, I., et al. (2006). ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clinical Cancer Research, 12, 7149\u20137158.","journal-title":"Clinical Cancer Research"},{"key":"9344_CR40","first-page":"1061","volume":"20","author":"MM Baekelandt","year":"2000","unstructured":"Baekelandt, M. M., Holm, R., Nesland, J. M., Trope, C. G., & Kristensen, G. B. (2000). P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Research, 20, 1061\u20131067.","journal-title":"Anticancer Research"},{"key":"9344_CR41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3727\/000000006783980892","volume":"16","author":"L Lu","year":"2007","unstructured":"Lu, L., Katsaros, D., Wiley, A., Rigault de la Longrais, I. A., Puopolo, M., & Yu, H. (2007). Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncology Research, 16, 395\u2013403.","journal-title":"Oncology Research"},{"key":"9344_CR42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/carcin\/bgi176","volume":"27","author":"AE Herwaarden van","year":"2006","unstructured":"van Herwaarden, A. E., Wagenaar, E., Karnekamp, B., Merino, G., Jonker, J. W., & Schinkel, A. H. (2006). Breast cancer resistance protein (Bcrp1\/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis, 27, 123\u2013130.","journal-title":"Carcinogenesis"},{"key":"9344_CR43","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","volume":"7","author":"S Zhou","year":"2001","unstructured":"Zhou, S., Schuetz, J. D., Bunting, K. D., et al. (2001). The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine, 7, 1028\u20131034.","journal-title":"Nature Medicine"},{"key":"9344_CR44","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/bcr563","volume":"5","author":"AJ Alvi","year":"2003","unstructured":"Alvi, A. J., Clayton, H., Joshi, C., et al. (2003). Functional and molecular characterisation of mammary side population cells. Breast Cancer Research, 5, R1\u2013R8.","journal-title":"Breast Cancer Research"},{"key":"9344_CR45","doi-asserted-by":"crossref","first-page":"e10964","DOI":"10.1371\/journal.pone.0010964","volume":"5","author":"I Cervello","year":"2010","unstructured":"Cervello, I., Gil-Sanchis, C., Mas, A., et al. (2010). Human endometrial side population cells exhibit genotypic, phenotypic and functional features of somatic stem cells. PLoS One, 5, e10964.","journal-title":"PLoS One"},{"key":"9344_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13577-010-0002-z","volume":"24","author":"S Hosonuma","year":"2011","unstructured":"Hosonuma, S., Kobayashi, Y., Kojo, S., et al. (2011). Clinical significance of side population in ovarian cancer cells. Human Cell, 24, 9\u201312.","journal-title":"Human Cell"},{"key":"9344_CR47","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","volume":"103","author":"PP Szotek","year":"2006","unstructured":"Szotek, P. P., Pieretti-Vanmarcke, R., Masiakos, P. T., et al. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proceedings of the National Academy of Sciences of the United States of America, 103, 11154\u201311159.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9344_CR48","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.bjc.6605626","volume":"102","author":"L Hu","year":"2010","unstructured":"Hu, L., McArthur, C., & Jaffe, R. B. (2010). Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. British Journal of Cancer, 102, 1276\u20131283.","journal-title":"British Journal of Cancer"},{"key":"9344_CR49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/djh095","volume":"96","author":"RJ Jones","year":"2004","unstructured":"Jones, R. J., Matsui, W. H., & Smith, B. D. (2004). Cancer stem cells: are we missing the target? Journal of the National Cancer Institute, 96, 583\u2013585.","journal-title":"Journal of the National Cancer Institute"},{"key":"9344_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drup.2010.12.002","volume":"14","author":"H Burger","year":"2011","unstructured":"Burger, H., Loos, W. J., Eechoute, K., Verweij, J., Mathijssen, R. H. J., & Wiemer, E. A. C. (2011). Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resistance Updates, 14, 22\u201334.","journal-title":"Drug Resistance Updates"},{"key":"9344_CR51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/gyno.2002.6738","volume":"86","author":"S Kamazawa","year":"2002","unstructured":"Kamazawa, S., Kigawa, J., Kanamori, Y., et al. (2002). Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecologic Oncology, 86, 171\u2013176.","journal-title":"Gynecologic Oncology"},{"key":"9344_CR52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2407-10-133","volume":"10","author":"GF Yang","year":"2010","unstructured":"Yang, G. F., He, W. P., Cai, M. Y., et al. (2010). Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer, 10, 133.","journal-title":"BMC Cancer"},{"key":"9344_CR53","doi-asserted-by":"crossref","first-page":"e17918","DOI":"10.1371\/journal.pone.0017918","volume":"6","author":"E Wang","year":"2011","unstructured":"Wang, E., Bhattacharyya, S., Szabolcs, A., et al. (2011). Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One, 6, e17918.","journal-title":"PLoS One"},{"key":"9344_CR54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/pgs.10.32","volume":"11","author":"C Rodriguez-Antona","year":"2010","unstructured":"Rodriguez-Antona, C. (2010). Pharmacogenomics of paclitaxel. Pharmacogenomics, 11, 621\u2013623.","journal-title":"Pharmacogenomics"},{"key":"9344_CR55","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-05-3153","volume":"66","author":"MS Wicha","year":"2006","unstructured":"Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: an old idea\u2013a paradigm shift. Cancer Research, 66, 1883\u20131890. discussion 95-6.","journal-title":"Cancer Research"},{"key":"9344_CR56","first-page":"6","volume":"70","author":"S Sell","year":"1994","unstructured":"Sell, S., & Pierce, G. B. (1994). Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Laboratory Investigation, 70, 6\u201322.","journal-title":"Laboratory Investigation"},{"key":"9344_CR57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/305779a0","volume":"305","author":"WK Cavenee","year":"1983","unstructured":"Cavenee, W. K., Dryja, T. P., Phillips, R. A., et al. (1983). Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature, 305, 779\u2013784.","journal-title":"Nature"},{"key":"9344_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(08)60313-9","volume":"62","author":"PC Nowell","year":"1993","unstructured":"Nowell, P. C. (1993). Foundations in cancer research. Chromosomes and cancer: the evolution of an idea. Advances in Cancer Research, 62, 1\u201317.","journal-title":"Advances in Cancer Research"},{"key":"9344_CR59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s000180050270","volume":"55","author":"RR Wallace-Brodeur","year":"1999","unstructured":"Wallace-Brodeur, R. R., & Lowe, S. W. (1999). Clinical implications of p53 mutations. Cellular and Molecular Life Sciences, 55, 64\u201375.","journal-title":"Cellular and Molecular Life Sciences"},{"key":"9344_CR60","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V98.9.2603","volume":"98","author":"I Herr","year":"2001","unstructured":"Herr, I., & Debatin, K. M. (2001). Cellular stress response and apoptosis in cancer therapy. Blood, 98, 2603\u20132614.","journal-title":"Blood"},{"key":"9344_CR61","first-page":"144","volume":"18","author":"EC Reed","year":"1999","unstructured":"Reed, E. C. (1999). Cancer Chemotherapy and Biological Response Modifiers, 18, 144\u2013151.","journal-title":"Cancer Chemotherapy and Biological Response Modifiers"},{"key":"9344_CR62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","volume":"18","author":"CD Rolitsky","year":"1999","unstructured":"Rolitsky, C. D., Theil, K. S., McGaughy, V. R., Copeland, L. J., & Niemann, T. H. (1999). HER-2\/neu amplification and overexpression in endometrial carcinoma. International Journal of Gynecological Pathology, 18, 138\u2013143.","journal-title":"International Journal of Gynecological Pathology"},{"key":"9344_CR63","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J., Godolphin, W., Jones, L. A., et al. (1989). Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707\u2013712.","journal-title":"Science"},{"key":"9344_CR64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF01269885","volume":"123","author":"JW Kim","year":"1997","unstructured":"Kim, J. W., Lee, C. G., Lyu, M. S., et al. (1997). A new cell line from human undifferentiated carcinoma of the ovary: establishment and characterization. Journal of Cancer Research and Clinical Oncology, 123, 82\u201390.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"9344_CR65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/emboj.2008.253","volume":"28","author":"M Perez-Caro","year":"2009","unstructured":"Perez-Caro, M., Cobaleda, C., Gonzalez-Herrero, I., et al. (2009). Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO Journal, 28, 8\u201320.","journal-title":"EMBO Journal"},{"key":"9344_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/REP-09-0389","volume":"140","author":"SA Bapat","year":"2010","unstructured":"Bapat, S. A. (2010). Human ovarian cancer stem cells. Reproduction, 140, 33\u201341.","journal-title":"Reproduction"},{"key":"9344_CR67","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1371\/journal.pmed.1000025","volume":"6","author":"K Lawrenson","year":"2009","unstructured":"Lawrenson, K., & Gayther, S. A. (2009). Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Medicine, 6, e25.","journal-title":"PLoS Medicine"},{"key":"9344_CR68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4161\/mabs.1.1.7347","volume":"1","author":"MP Deonarain","year":"2009","unstructured":"Deonarain, M. P., Kousparou, C. A., & Epenetos, A. A. (2009). Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs, 1, 12\u201325.","journal-title":"MAbs"},{"key":"9344_CR69","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1525-1438.2007.01056.x","volume":"18","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina, G., Bonanno, G., Pierelli, L., et al. (2008). Expression of CD133-1 and CD133-2 in ovarian cancer. International Journal of Gynecological Cancer, 18, 506\u2013514.","journal-title":"International Journal of Gynecological Cancer"},{"key":"9344_CR70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.bjc.6604437","volume":"99","author":"LM Smith","year":"2008","unstructured":"Smith, L. M., Nesterova, A., Ryan, M. C., et al. (2008). CD133\/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. British Journal of Cancer, 99, 100\u2013109.","journal-title":"British Journal of Cancer"},{"key":"9344_CR71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-230X(08)60101-3","volume":"71","author":"D Naor","year":"1997","unstructured":"Naor, D., Sionov, R. V., & Ish-Shalom, D. (1997). CD44: structure, function, and association with the malignant process. Advances in Cancer Research, 71, 241\u2013319.","journal-title":"Advances in Cancer Research"},{"key":"9344_CR72","doi-asserted-by":"crossref","first-page":"620523","DOI":"10.1155\/2011\/620523","volume":"2011","author":"KD Steffensen","year":"2011","unstructured":"Steffensen, K. D., Alvero, A. B., Yang, Y., et al. (2011). Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol, 2011, 620523.","journal-title":"J Oncol"},{"key":"9344_CR73","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","volume":"8","author":"AB Alvero","year":"2009","unstructured":"Alvero, A. B., Chen, R., Fu, H. H., et al. (2009). Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 8, 158\u2013166.","journal-title":"Cell Cycle"},{"key":"9344_CR74","doi-asserted-by":"crossref","unstructured":"Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46:1271\u20137.","DOI":"10.1016\/j.ejca.2010.02.024"},{"key":"9344_CR75","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00262-003-0494-4","volume":"53","author":"KH Heider","year":"2004","unstructured":"Heider, K. H., Kuthan, H., Stehle, G., & Munzert, G. (2004). CD44v6: a target for antibody-based cancer therapy. Cancer Immunology, Immunotherapy, 53, 567\u2013579.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"9344_CR76","unstructured":"De Stefano I, Battaglia A, Zannoni GF, et al. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol."},{"key":"9344_CR77","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews. Cancer, 8, 755\u2013768.","journal-title":"Nature Reviews. Cancer"},{"key":"9344_CR78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/IGC.0b013e3181a8331f","volume":"19","author":"S Bellone","year":"2009","unstructured":"Bellone, S., Siegel, E. R., Cocco, E., et al. (2009). Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent\/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. International Journal of Gynecological Cancer, 19, 860\u2013866.","journal-title":"International Journal of Gynecological Cancer"},{"key":"9344_CR79","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2008.18.5710","volume":"27","author":"AL Fields","year":"2009","unstructured":"Fields, A. L., Keller, A., Schwartzberg, L., et al. (2009). Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. Journal of Clinical Oncology, 27, 1941\u20131947.","journal-title":"Journal of Clinical Oncology"},{"key":"9344_CR80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00432-003-0438-6","volume":"129","author":"W Xiang","year":"2003","unstructured":"Xiang, W., Wimberger, P., Dreier, T., et al. (2003). Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. Journal of Cancer Research and Clinical Oncology, 129, 341\u2013348.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"9344_CR81","doi-asserted-by":"crossref","unstructured":"Richter CE, Cocco E, Bellone S, et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol 203:582 e1\u20137.","DOI":"10.1016\/j.ajog.2010.07.041"},{"key":"9344_CR82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","volume":"10","author":"JI Fletcher","year":"2010","unstructured":"Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010). ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews. Cancer, 10, 147\u2013156.","journal-title":"Nature Reviews. Cancer"},{"key":"9344_CR83","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/bies.200900058","volume":"31","author":"T Schatton","year":"2009","unstructured":"Schatton, T., Frank, N. Y., & Frank, M. H. (2009). Identification and targeting of cancer stem cells. Bioessays, 31, 1038\u20131049.","journal-title":"Bioessays"},{"issue":"10","key":"9344_CR84","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/sj.leu.2401150","volume":"12","author":"SL Soignet","year":"1998","unstructured":"Soignet, S. L., Benedetti, F., Fleischauer, A., et al. (1998). Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia. Leukemia, 12(10), 1518\u20131521.","journal-title":"Leukemia"},{"key":"9344_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2004.04.007","volume":"51","author":"S Sell","year":"2004","unstructured":"Sell, S. (2004). Stem cell origin of cancer and differentiation therapy. Critical Reviews in Oncology\/Hematology, 51, 1\u201328.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"9344_CR86","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/bcr2871","volume":"13","author":"OA Stefansson","year":"2011","unstructured":"Stefansson, O. A., & Esteller, M. (2011). EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells. Breast Cancer Research, 13, 309.","journal-title":"Breast Cancer Research"},{"key":"9344_CR87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccr.2010.10.035","volume":"19","author":"CJ Chang","year":"2011","unstructured":"Chang, C. J., Yang, J. Y., Xia, W., et al. (2011). EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell, 19, 86\u2013100.","journal-title":"Cancer Cell"},{"key":"9344_CR88","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/sj.embor.7400441","volume":"6","author":"A Taddei","year":"2005","unstructured":"Taddei, A., Roche, D., Bickmore, W. A., & Almouzni, G. (2005). The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Reports, 6, 520\u2013524.","journal-title":"EMBO Reports"},{"key":"9344_CR89","first-page":"8188","volume":"61","author":"M Bergmann","year":"2001","unstructured":"Bergmann, M., Romirer, I., Sachet, M., et al. (2001). A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Research, 61, 8188\u20138193.","journal-title":"Cancer Research"},{"key":"9344_CR90","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/carcin\/bgh293","volume":"26","author":"F Behbod","year":"2005","unstructured":"Behbod, F., & Rosen, J. M. (2005). Will cancer stem cells provide new therapeutic targets? Carcinogenesis, 26, 703\u2013711.","journal-title":"Carcinogenesis"},{"key":"9344_CR91","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.4161\/cc.4.11.2208","volume":"4","author":"MV Blagosklonny","year":"2005","unstructured":"Blagosklonny, M. V. (2005). Teratogens as anti-cancer drugs. Cell Cycle, 4, 1518\u20131521.","journal-title":"Cell Cycle"},{"key":"9344_CR92","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/35023008","volume":"406","author":"J Taipale","year":"2000","unstructured":"Taipale, J., Chen, J. K., Cooper, M. K., et al. (2000). Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature, 406, 1005\u20131009.","journal-title":"Nature"},{"key":"9344_CR93","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1073\/pnas.0611682104","volume":"104","author":"CD Peacock","year":"2007","unstructured":"Peacock, C. D., Wang, Q., Gesell, G. S., et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 104, 4048\u20134053.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9344_CR94","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2004-01-0395","volume":"104","author":"DE Banker","year":"2004","unstructured":"Banker, D. E., Mayer, S. J., Li, H. Y., Willman, C. L., Appelbaum, F. R., & Zager, R. A. (2004). Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood, 104, 1816\u20131824.","journal-title":"Blood"},{"key":"9344_CR95","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0145-2126(02)00085-1","volume":"27","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt, D. L., Appelbaum, F. R., Willman, C. L., Zager, R. A., & Banker, D. E. (2003). Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leukemia Research, 27, 133\u2013145.","journal-title":"Leukemia Research"},{"key":"9344_CR96","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1158\/0008-5472.CAN-04-0866","volume":"64","author":"J Wu","year":"2004","unstructured":"Wu, J., Wong, W. W., Khosravi, F., Minden, M. D., & Penn, L. Z. (2004). Blocking the Raf\/MEK\/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Research, 64, 6461\u20136468.","journal-title":"Cancer Research"},{"key":"9344_CR97","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2404245","volume":"20","author":"AM Martelli","year":"2006","unstructured":"Martelli, A. M., Nyakern, M., Tabellini, G., et al. (2006). Phosphoinositide 3-kinase\/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia, 20, 911\u2013928.","journal-title":"Leukemia"},{"key":"9344_CR98","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.molmed.2007.09.003","volume":"13","author":"DS Krause","year":"2007","unstructured":"Krause, D. S., & Van Etten, R. A. (2007). Right on target: eradicating leukemic stem cells. Trends in Molecular Medicine, 13, 470\u2013481.","journal-title":"Trends in Molecular Medicine"},{"key":"9344_CR99","first-page":"141","volume":"89","author":"S Kersten","year":"2000","unstructured":"Kersten, S., & Wahli, W. (2000). Peroxisome proliferator activated receptor agonists. EXS, 89, 141\u2013151.","journal-title":"EXS"},{"key":"9344_CR100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","volume":"5","author":"C Grommes","year":"2004","unstructured":"Grommes, C., Landreth, G. E., & Heneka, M. T. (2004). Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. The Lancet Oncology, 5, 419\u2013429.","journal-title":"The Lancet Oncology"},{"key":"9344_CR101","first-page":"1","volume":"9","author":"HP Koeffler","year":"2003","unstructured":"Koeffler, H. P. (2003). Peroxisome proliferator-activated receptor gamma and cancers. Clinical Cancer Research, 9, 1\u20139.","journal-title":"Clinical Cancer Research"},{"key":"9344_CR102","first-page":"357","volume":"1","author":"L Kopelovich","year":"2002","unstructured":"Kopelovich, L., Fay, J. R., Glazer, R. I., & Crowell, J. A. (2002). Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Molecular Cancer Therapeutics, 1, 357\u2013363.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9344_CR103","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.94.1.237","volume":"94","author":"P Tontonoz","year":"1997","unstructured":"Tontonoz, P., Singer, S., Forman, B. M., et al. (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proceedings of the National Academy of Sciences of the United States of America, 94, 237\u2013241.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9344_CR104","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/2030","volume":"4","author":"P Sarraf","year":"1998","unstructured":"Sarraf, P., Mueller, E., Jones, D., et al. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nature Medicine, 4, 1046\u20131052.","journal-title":"Nature Medicine"},{"key":"9344_CR105","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1242\/dev.124.10.1929","volume":"124","author":"SJ Morrison","year":"1997","unstructured":"Morrison, S. J., Wandycz, A. M., Hemmati, H. D., Wright, D. E., & Weissman, I. L. (1997). Identification of a lineage of multipotent hematopoietic progenitors. Development, 124, 1929\u20131939.","journal-title":"Development"},{"key":"9344_CR106","doi-asserted-by":"crossref","unstructured":"Ruiz-Vela, A., Aguilar-Gallardo, C., Martinez-Arroyo, A.M., Soriano-Navarro, M., Ruiz, V., Simon, C. (2011). Specific unsaturated fatty acids enforce the transdifferentiation of human cancer cells toward adipocyte-like cells. Stem Cell Rev.","DOI":"10.1007\/s12015-011-9253-7"},{"key":"9344_CR107","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1172\/JCI28003","volume":"116","author":"RK Semple","year":"2006","unstructured":"Semple, R. K., Chatterjee, V. K., & O\u2019Rahilly, S. (2006). PPAR gamma and human metabolic disease. The Journal of Clinical Investigation, 116, 581\u2013589.","journal-title":"The Journal of Clinical Investigation"},{"key":"9344_CR108","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1593\/neo.06433","volume":"8","author":"S Vignati","year":"2006","unstructured":"Vignati, S., Albertini, V., Rinaldi, A., et al. (2006). Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia, 8, 851\u2013861.","journal-title":"Neoplasia"},{"key":"9344_CR109","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1535-7163.993.3.8","volume":"3","author":"CM Holland","year":"2004","unstructured":"Holland, C. M., Saidi, S. A., Evans, A. L., et al. (2004). Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Molecular Cancer Therapeutics, 3, 993\u20131001.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9344_CR110","first-page":"833","volume":"18","author":"T Shigeto","year":"2007","unstructured":"Shigeto, T., Yokoyama, Y., Xin, B., & Mizunuma, H. (2007). Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncology Reports, 18, 833\u2013840.","journal-title":"Oncology Reports"},{"key":"9344_CR111","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.22854","volume":"110","author":"B Xin","year":"2007","unstructured":"Xin, B., Yokoyama, Y., Shigeto, T., Futagami, M., & Mizunuma, H. (2007). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer, 110, 791\u2013800.","journal-title":"Cancer"},{"key":"9344_CR112","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1525-1438.2006.00866.x","volume":"17","author":"YC Yang","year":"2007","unstructured":"Yang, Y. C., Tsao, Y. P., Ho, T. C., & Choung, I. P. (2007). Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. International Journal of Gynecological Cancer, 17, 418\u2013425.","journal-title":"International Journal of Gynecological Cancer"},{"key":"9344_CR113","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","volume":"110","author":"WH Gotlieb","year":"2008","unstructured":"Gotlieb, W. H., Saumet, J., Beauchamp, M. C., et al. (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 110, 246\u2013250.","journal-title":"Gynecologic Oncology"},{"key":"9344_CR114","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1593\/neo.11148","volume":"13","author":"R Rattan","year":"2011","unstructured":"Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. (2011). Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 13, 483\u2013491.","journal-title":"Neoplasia"},{"key":"9344_CR115","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","volume":"69","author":"HA Hirsch","year":"2009","unstructured":"Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research, 69, 7507\u20137511.","journal-title":"Cancer Research"},{"key":"9344_CR116","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis, M. E., Chen, Z. G., & Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews. Drug Discovery, 7, 771\u2013782.","journal-title":"Nature Reviews. Drug Discovery"},{"key":"9344_CR117","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2010.08.001","volume":"16","author":"ZG Chen","year":"2010","unstructured":"Chen, Z. G. (2010). Small-molecule delivery by nanoparticles for anticancer therapy. Trends in Molecular Medicine, 16, 594\u2013602.","journal-title":"Trends in Molecular Medicine"},{"key":"9344_CR118","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11095-006-9223-y","volume":"24","author":"D Sutton","year":"2007","unstructured":"Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007). Functionalized micellar systems for cancer targeted drug delivery. Pharmaceutical Research, 24, 1029\u20131046.","journal-title":"Pharmaceutical Research"},{"key":"9344_CR119","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1158\/1078-0432.CCR-05-0803","volume":"11","author":"AV Boddy","year":"2005","unstructured":"Boddy, A. V., Plummer, E. R., Todd, R., et al. (2005). A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clinical Cancer Research, 11, 7834\u20137840.","journal-title":"Clinical Cancer Research"},{"key":"9344_CR120","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2004.12.043","volume":"22","author":"P Sabbatini","year":"2004","unstructured":"Sabbatini, P., Aghajanian, C., Dizon, D., et al. (2004). Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Journal of Clinical Oncology, 22, 4523\u20134531.","journal-title":"Journal of Clinical Oncology"},{"key":"9344_CR121","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.biomaterials.2011.01.073","volume":"32","author":"A Eldar-Boock","year":"2011","unstructured":"Eldar-Boock, A., Miller, K., Sanchis, J., Lupu, R., Vicent, M. J., & Satchi-Fainaro, R. (2011). Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials, 32, 3862\u20133874.","journal-title":"Biomaterials"},{"key":"9344_CR122","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman, J. (2007). Angiogenesis: an organizing principle for drug discovery? Nature Reviews. Drug Discovery, 6, 273\u2013286.","journal-title":"Nature Reviews. Drug Discovery"},{"key":"9344_CR123","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1677\/ERC-10-0148","volume":"18","author":"S Leskela","year":"2011","unstructured":"Leskela, S., Leandro-Garcia, L. J., Mendiola, M., et al. (2011). The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocrine-Related Cancer, 18, 85\u201395.","journal-title":"Endocrine-Related Cancer"},{"key":"9344_CR124","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1074\/jbc.C800074200","volume":"283","author":"M Korpal","year":"2008","unstructured":"Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry, 283, 14910\u201314914.","journal-title":"Journal of Biological Chemistry"},{"key":"9344_CR125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2009.05.022","volume":"114","author":"X Hu","year":"2009","unstructured":"Hu, X., Macdonald, D. M., Huettner, P. C., et al. (2009). A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology, 114, 457\u2013464.","journal-title":"Gynecologic Oncology"},{"key":"9344_CR126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2011.03.026","volume":"122","author":"Q Wu","year":"2011","unstructured":"Wu, Q., Guo, R., Lin, M., Zhou, B., & Wang, Y. (2011). MicroRNA-200a inhibits CD133\/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecologic Oncology, 122, 149\u2013154.","journal-title":"Gynecologic Oncology"},{"key":"9344_CR127","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1158\/0008-5472.CAN-09-2552","volume":"69","author":"R Bhattacharya","year":"2009","unstructured":"Bhattacharya, R., Nicoloso, M., Arvizo, R., et al. (2009). MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Research, 69, 9090\u20139095.","journal-title":"Cancer Research"},{"issue":"Suppl 2","key":"9344_CR128","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/modpathol.3800306","volume":"18","author":"DA Bell","year":"2005","unstructured":"Bell, D. A. (2005). Origins and molecular pathology of ovarian cancer. Modern Pathology, 18(Suppl 2), S19\u2013S32.","journal-title":"Modern Pathology"},{"key":"9344_CR129","first-page":"1299","volume":"20","author":"Y Saga","year":"2008","unstructured":"Saga, Y., Ohwada, M., Suzuki, M., et al. (2008). Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncology Reports, 20, 1299\u20131303.","journal-title":"Oncology Reports"},{"key":"9344_CR130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast, R. C., Jr., Hennessy, B., & Mills, G. B. (2009). The biology of ovarian cancer: new opportunities for translation. Nature Reviews. Cancer, 9, 415\u2013428.","journal-title":"Nature Reviews. Cancer"},{"key":"9344_CR131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2010.02.010","volume":"117","author":"M Frumovitz","year":"2010","unstructured":"Frumovitz, M., Schmeler, K. M., Malpica, A., Sood, A. K., & Gershenson, D. M. (2010). Unmasking the complexities of mucinous ovarian carcinoma. Gynecologic Oncology, 117, 491\u2013496.","journal-title":"Gynecologic Oncology"},{"key":"9344_CR132","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.humpath.2009.04.017","volume":"40","author":"CB Gilks","year":"2009","unstructured":"Gilks, C. B., & Prat, J. (2009). Ovarian carcinoma pathology and genetics: recent advances. Human Pathology, 40, 1213\u20131223.","journal-title":"Human Pathology"},{"key":"9344_CR133","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/cncr.23438","volume":"112","author":"DJ Storey","year":"2008","unstructured":"Storey, D. J., Rush, R., Stewart, M., et al. (2008). Endometrioid epithelial ovarian cancer: 20\u00a0years of prospectively collected data from a single center. Cancer, 112, 2211\u20132220.","journal-title":"Cancer"},{"key":"9344_CR134","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/er.22.2.255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K., & Leung, P. C. (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocrine Reviews, 22, 255\u2013288.","journal-title":"Endocrine Reviews"},{"key":"9344_CR135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106\u2013110.","journal-title":"Nature"},{"key":"9344_CR136","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/ijc.22476","volume":"120","author":"S Yin","year":"2007","unstructured":"Yin, S., Li, J., Hu, C., et al. (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. International Journal of Cancer, 120, 1444\u20131450.","journal-title":"International Journal of Cancer"},{"key":"9344_CR137","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1634\/stemcells.2008-0601","volume":"26","author":"G Rappa","year":"2008","unstructured":"Rappa, G., Fodstad, O., & Lorico, A. (2008). The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells, 26, 3008\u20133017.","journal-title":"Stem Cells"},{"key":"9344_CR138","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/1541-7786.MCR-09-0383","volume":"8","author":"JM Angelastro","year":"2010","unstructured":"Angelastro, J. M., & Lame, M. W. (2010). Overexpression of CD133 promotes drug resistance in C6 glioma cells. Molecular Cancer Research, 8, 1105\u20131115.","journal-title":"Molecular Cancer Research"},{"key":"9344_CR139","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3892\/or_00000865","volume":"24","author":"S Saigusa","year":"2010","unstructured":"Saigusa, S., Tanaka, K., Toiyama, Y., et al. (2010). Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncology Reports, 24, 345\u2013350.","journal-title":"Oncology Reports"},{"key":"9344_CR140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00022744-200112000-00004","volume":"9","author":"AM Afify","year":"2001","unstructured":"Afify, A. M., Ferguson, A. W., Davila, R. M., & Werness, B. A. (2001). Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Applied Immunohistochemistry & Molecular Morphology, 9, 309\u2013314.","journal-title":"Applied Immunohistochemistry & Molecular Morphology"},{"key":"9344_CR141","first-page":"5318","volume":"9","author":"S Sillanpaa","year":"2003","unstructured":"Sillanpaa, S., Anttila, M. A., Voutilainen, K., et al. (2003). CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clinical Cancer Research, 9, 5318\u20135324.","journal-title":"Clinical Cancer Research"},{"key":"9344_CR142","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/ijc.24573","volume":"125","author":"SP Hong","year":"2009","unstructured":"Hong, S. P., Wen, J., Bang, S., Park, S., & Song, S. Y. (2009). CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. International Journal of Cancer, 125, 2323\u20132331.","journal-title":"International Journal of Cancer"},{"key":"9344_CR143","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/07357900902744502","volume":"27","author":"D Horst","year":"2009","unstructured":"Horst, D., Kriegl, L., Engel, J., Kirchner, T., & Jung, A. (2009). Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Investigation, 27, 844\u2013850.","journal-title":"Cancer Investigation"},{"key":"9344_CR144","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/stem.30","volume":"27","author":"S Takaishi","year":"2009","unstructured":"Takaishi, S., Okumura, T., Tu, S., et al. (2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells, 27, 1006\u20131020.","journal-title":"Stem Cells"},{"key":"9344_CR145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbrc.2010.05.041","volume":"397","author":"C Oliveras-Ferraros","year":"2010","unstructured":"Oliveras-Ferraros, C., Vazquez-Martin, A., Martin-Castillo, B., et al. (2010). Dynamic emergence of the mesenchymal CD44(pos)CD24(neg\/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications, 397, 27\u201333.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"9344_CR146","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CMR.0b013e3283350554","volume":"20","author":"V Sviatoha","year":"2010","unstructured":"Sviatoha, V., Tani, E., Kleina, R., Sperga, M., & Skoog, L. (2010). Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours. Melanoma Research, 20, 118\u2013125.","journal-title":"Melanoma Research"},{"key":"9344_CR147","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-4608(02)00855-5","volume":"143","author":"HR Abeysinghe","year":"2003","unstructured":"Abeysinghe, H. R., Cao, Q., Xu, J., et al. (2003). THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genetics and Cytogenetics, 143, 125\u2013132.","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"9344_CR148","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1038\/sj.onc.1208812","volume":"24","author":"HL Lung","year":"2005","unstructured":"Lung, H. L., Bangarusamy, D. K., Xie, D., et al. (2005). THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene, 24, 6525\u20136532.","journal-title":"Oncogene"},{"key":"9344_CR149","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2008.01.013","volume":"13","author":"ZF Yang","year":"2008","unstructured":"Yang, Z. F., Ho, D. W., Ng, M. N., et al. (2008). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell, 13, 153\u2013166.","journal-title":"Cancer Cell"},{"key":"9344_CR150","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0002-9440(10)64398-2","volume":"161","author":"G Kristiansen","year":"2002","unstructured":"Kristiansen, G., Denkert, C., Schluns, K., Dahl, E., Pilarsky, C., & Hauptmann, S. (2002). CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. American Journal of Pathology, 161, 1215\u20131221.","journal-title":"American Journal of Pathology"},{"key":"9344_CR151","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.urology.2008.01.061","volume":"72","author":"HJ Lee","year":"2008","unstructured":"Lee, H. J., Kim, D. I., Kwak, C., Ku, J. H., & Moon, K. C. (2008). Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology, 72, 603\u2013607.","journal-title":"Urology"},{"key":"9344_CR152","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12253-008-9077-1","volume":"15","author":"B Nagy","year":"2009","unstructured":"Nagy, B., Szendroi, A., & Romics, I. (2009). Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathology Oncology Research, 15, 279\u2013283.","journal-title":"Pathology Oncology Research"},{"key":"9344_CR153","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1158\/1078-0432.CCR-09-0151","volume":"15","author":"XR Yang","year":"2009","unstructured":"Yang, X. R., Xu, Y., Yu, B., et al. (2009). CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clinical Cancer Research, 15, 5518\u20135527.","journal-title":"Clinical Cancer Research"},{"key":"9344_CR154","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1349-7006.2009.01378.x","volume":"101","author":"H Kajiyama","year":"2010","unstructured":"Kajiyama, H., Shibata, K., Ino, K., Mizutani, S., Nawa, A., & Kikkawa, F. (2010). The expression of dipeptidyl peptidase IV (DPPIV\/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Science, 101, 347\u2013354.","journal-title":"Cancer Science"},{"key":"9344_CR155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.stem.2010.04.001","volume":"6","author":"R Pang","year":"2010","unstructured":"Pang, R., Law, W. L., Chu, A. C., et al. (2010). A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell, 6, 603\u2013615.","journal-title":"Cell Stem Cell"},{"key":"9344_CR156","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.mpa.0000202961.71600.9b","volume":"32","author":"H Wei","year":"2006","unstructured":"Wei, H., Wang, C., & Chen, L. (2006). Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha. Pancreas, 32, 159\u2013163.","journal-title":"Pancreas"},{"key":"9344_CR157","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.canlet.2008.05.011","volume":"270","author":"SJ Shin","year":"2008","unstructured":"Shin, S. J., Jeung, H. C., Ahn, J. B., et al. (2008). Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Cancer Letters, 270, 269\u2013276.","journal-title":"Cancer Letters"},{"key":"9344_CR158","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","volume":"116","author":"X Jiang","year":"2010","unstructured":"Jiang, X., Forrest, D., Nicolini, F., et al. (2010). Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 116, 2112\u20132121.","journal-title":"Blood"},{"key":"9344_CR159","unstructured":"Liu, L., Chen, R., Huang, S., et al. (2010). Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Med Oncol."},{"key":"9344_CR160","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1111\/j.1582-4934.2009.00723.x","volume":"13","author":"AV Salnikov","year":"2009","unstructured":"Salnikov, A. V., Groth, A., Apel, A., et al. (2009). Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. Journal of Cellular and Molecular Medicine, 13, 4023\u20134033.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"9344_CR161","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2008.12.004","volume":"136","author":"T Yamashita","year":"2009","unstructured":"Yamashita, T., Ji, J., Budhu, A., et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem\/progenitor cell features. Gastroenterology, 136, 1012\u20131024.","journal-title":"Gastroenterology"},{"key":"9344_CR162","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2009.10.026","volume":"52","author":"B Terris","year":"2010","unstructured":"Terris, B., Cavard, C., & Perret, C. (2010). EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. Journal of Hepatology, 52, 280\u2013281.","journal-title":"Journal of Hepatology"},{"key":"9344_CR163","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0065-2571(88)90019-2","volume":"27","author":"M Colvin","year":"1988","unstructured":"Colvin, M., Russo, J. E., Hilton, J., Dulik, D. M., & Fenselau, C. (1988). Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Advances in Enzyme Regulation, 27, 211\u2013221.","journal-title":"Advances in Enzyme Regulation"},{"key":"9344_CR164","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1021\/bi00413a022","volume":"27","author":"A Eastman","year":"1988","unstructured":"Eastman, A., & Schulte, N. (1988). Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27, 4730\u20134734.","journal-title":"Biochemistry"},{"key":"9344_CR165","doi-asserted-by":"crossref","first-page":"23197","DOI":"10.1016\/S0021-9258(17)31639-3","volume":"269","author":"KD Bunting","year":"1994","unstructured":"Bunting, K. D., Lindahl, R., & Townsend, A. J. (1994). Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. Journal of Biological Chemistry, 269, 23197\u201323203.","journal-title":"Journal of Biological Chemistry"},{"key":"9344_CR166","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1158\/0008-5472.CAN-09-1132","volume":"69","author":"JE Carpentino","year":"2009","unstructured":"Carpentino, J. E., Hynes, M. J., Appelman, H. D., et al. (2009). Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Research, 69, 8208\u20138215.","journal-title":"Cancer Research"},{"key":"9344_CR167","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbrc.2009.05.048","volume":"385","author":"YC Chen","year":"2009","unstructured":"Chen, Y. C., Chen, Y. W., Hsu, H. S., et al. (2009). Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochemical and Biophysical Research Communications, 385, 307\u2013313.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"9344_CR168","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1349-7006.2009.01151.x","volume":"100","author":"K Morimoto","year":"2009","unstructured":"Morimoto, K., Kim, S. J., Tanei, T., et al. (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Science, 100, 1062\u20131068.","journal-title":"Cancer Science"},{"key":"9344_CR169","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/labinvest.2009.127","volume":"90","author":"T Li","year":"2010","unstructured":"Li, T., Su, Y., Mei, Y., et al. (2010). ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients\u2019 outcome. Laboratory Investigation, 90, 234\u2013244.","journal-title":"Laboratory Investigation"},{"key":"9344_CR170","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.4161\/cc.8.18.9504","volume":"8","author":"AM Bleau","year":"2009","unstructured":"Bleau, A. M., Huse, J. T., & Holland, E. C. (2009). The ABCG2 resistance network of glioblastoma. Cell Cycle, 8, 2936\u20132944.","journal-title":"Cell Cycle"},{"key":"9344_CR171","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus, C., Ozvegy-Laczka, C., Apati, A., et al. (2009). Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. British Journal of Pharmacology, 158, 1153\u20131164.","journal-title":"British Journal of Pharmacology"},{"key":"9344_CR172","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","volume":"334","author":"S Agarwal","year":"2010","unstructured":"Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F. (2010). Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. Journal of Pharmacology and Experimental Therapeutics, 334, 147\u2013155.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"9344_CR173","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.lfs.2010.02.012","volume":"86","author":"XW Ding","year":"2010","unstructured":"Ding, X. W., Wu, J. H., & Jiang, C. P. (2010). ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sciences, 86, 631\u2013637.","journal-title":"Life Sciences"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-011-9344-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12015-011-9344-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-011-9344-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:39:57Z","timestamp":1686703197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12015-011-9344-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,26]]},"references-count":173,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["9344"],"URL":"https:\/\/doi.org\/10.1007\/s12015-011-9344-5","relation":{},"ISSN":["1550-8943","1558-6804"],"issn-type":[{"value":"1550-8943","type":"print"},{"value":"1558-6804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,26]]}}}